Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first oral therapy

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

- PMLiVE

India revokes Roche’s Pegasys patent after patient group challenge

Company becomes latest in big pharma to see intellectual property overturned

- PMLiVE

Roche’s Avastin cleared in EU for recurrent ovarian cancer

Becomes first biologic to win approval for platinum-sensitive ovarian cancer

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

BMJ to only publish trials with open data

Comes as journal pushes Roche for full data on Tamiflu

Novartis building

NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

But draft guidance doesn't recommend Forest’s Colobreathe

Roche - Basel

EMA launches probe into Roche’s adverse event reporting

Pharma company allegedly failed to follow pharmacovigilance procedures

- PMLiVE

NICE and ABPI clash over access to medicines

Trade body says research shows medicines underused but NICE claims new figures 'higher than expected'

Roche - Basel

Roche Q3 sales up on cancer drugs

And CEO Schwan commits to gene sequencing despite failed Illumina bid

- PMLiVE

NICE stroke guidance boost for Boehringer’s Actilyse

Institute changes guidance on alteplase use

- PMLiVE

Lilly, Roche drugs selected for Alzheimer’s prevention study

Large-scale study will involve Roche's gantenerumab and Lilly's solanezumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links